REGN5459 Produces Durable Responses in Relapsed/Refractory Multiple Myeloma
REGN5459 appears safe and can produce durable responses in patients with relapsed or refractory multiple myeloma, a phase 1/2 study suggests.
Diagnosis & Disease Information
Neoadjuvant Vibostolimab Plus Pembrolizumab Demonstrates Activity in Melanoma
Neoadjuvant vibostolimab plus pembrolizumab has shown antitumor activity in a phase 1/2 trial of patients with stage IIIB-D melanoma.
Results With Atezolizumab and Bevacizumab May Prove Practice-Changing for HCC
Adjuvant treatment with atezolizumab and bevacizumab prolongs recurrence-free survival, when compared with active surveillance, in patients with hepatocellular carcinoma, a phase 3 study suggests.
Risk of Drug-Drug Interactions in Patients With HIV and Cancer
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
Pegargiminase Prolongs PFS, OS in Nonepithelioid Pleural Mesothelioma
Adding pegargiminase to standard frontline chemotherapy improves outcomes in patients with nonepithelioid pleural mesothelioma, a phase 2/3 study suggests.
Perioperative Durvalumab Improves Outcomes in Resectable NSCLC
Results from the AEGEAN trial suggest that adding perioperative durvalumab to neoadjuvant chemotherapy can improve outcomes in patients with resectable NSCLC.
Pembrolizumab May Be Treatment of Choice for Unresectable Desmoplastic Melanoma
In a phase 2 trial, pembrolizumab produced an overall response rate of 89% in patients with unresectable desmoplastic melanoma.
VT3989 Demonstrates Clinical Activity, Suggesting Hippo Pathway Is Druggable Target
The investigational drug VT3989 appears safe and can produce responses in patients with refractory mesothelioma or sarcoma, a phase 1 study suggests.
Frontline Pembrolizumab Improves OS in Advanced Biliary Tract Cancer
Adding pembrolizumab to frontline chemotherapy improves overall survival in patients with advanced biliary tract cancer, a phase 3 trial suggests.
Dabrafenib-Trametinib Combo Proves Active in Rare BRAF-Mutated Cancers
Combination dabrafenib and trametinib has demonstrated activity against multiple rare cancers harboring the BRAF V600E mutation.
- Loading...
Loading...
Next post in AACR 2023
Loading... 
Loading...